CYMBALTA Drug Patent Profile
✉ Email this page to a colleague
When do Cymbalta patents expire, and what generic alternatives are available?
Cymbalta is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in CYMBALTA is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cymbalta
A generic version of CYMBALTA was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CYMBALTA?
- What are the global sales for CYMBALTA?
- What is Average Wholesale Price for CYMBALTA?
Summary for CYMBALTA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 118 |
Clinical Trials: | 147 |
Patent Applications: | 4,502 |
Drug Prices: | Drug price information for CYMBALTA |
Drug Sales Revenues: | Drug sales revenues for CYMBALTA |
What excipients (inactive ingredients) are in CYMBALTA? | CYMBALTA excipients list |
DailyMed Link: | CYMBALTA at DailyMed |
Recent Clinical Trials for CYMBALTA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute, Egypt | Phase 4 |
Ain Shams University | Phase 4 |
GrĂ¼nenthal GmbH | Phase 3 |
Pharmacology for CYMBALTA
Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Paragraph IV (Patent) Challenges for CYMBALTA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CYMBALTA | Delayed-release Capsules | duloxetine hydrochloride | 40 mg | 021427 | 1 | 2012-05-10 |
CYMBALTA | Delayed-release Capsules | duloxetine hydrochloride | 20 mg, 30 mg and 60 mg | 021427 | 16 | 2008-08-04 |
US Patents and Regulatory Information for CYMBALTA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-001 | Aug 3, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-002 | Aug 3, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-004 | Aug 3, 2004 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CYMBALTA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-001 | Aug 3, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-002 | Aug 3, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-004 | Aug 3, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-002 | Aug 3, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-002 | Aug 3, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CYMBALTA
See the table below for patents covering CYMBALTA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2002524513 | ⤷ Sign Up | |
Hungary | 221502 | ENTERIC DULOXETINE FORMULATION | ⤷ Sign Up |
Spain | 2157297 | ⤷ Sign Up | |
Peru | 32196 | GRANULO ENTERICO DE DULOXETINA | ⤷ Sign Up |
Australia | 746887 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CYMBALTA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0273658 | C300171 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811 |
0273658 | C00273658/01 | Switzerland | ⤷ Sign Up | PRODUCT: DULOXETIN; REG. NO/DATE: SWISSMEDIC 56727 20041217; DER WIDERRUF VOM 05.03.2009 ERFOLGTE IRRTUEMLICH |
0693282 | PA2005001,C0693282 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DULOXETINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/04/280/001, EU/1/04/280/002, EU/1/04/280/003, EU/1/04/280/004, EU/1/04/280/005, EU/1/04/280/006 20040811 |
0273658 | 300171 | Netherlands | ⤷ Sign Up | 300171, 20071218, EXPIRES: 20121217 |
0273658 | 3/2005 | Austria | ⤷ Sign Up | PRODUCT NAME: 3-ARYLOXY-3-SUBSTITUIERTE-PROPANAMINE; REGISTRATION NO/DATE: EU/1/04/280/001 - EU/1/04/280/006 20040811 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |